Park Ha Biological Technology Co., Ltd. (BYAH)

Nasdaq: BYAH · Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics · Wuxi City, CN · filing with the SEC since 2023

Full chart Alerts Compare

Grade5.0

◀ Past 4.7● Present 4.3▶ Future 6.3

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Park Ha Biological Technology Co., Ltd.

Nine metrics read from its own filings, by tense

Headline grade

5.0/10

◀ Past4.730% of the headline

● Present4.340% of the headline

▶ Future6.330% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.7/1030% of the headline grade · 3 of 3 filed

Surviving crises

as filed

6.7/10

Has it survived what it has been through?

No warning events in its filings since 2023.

weight 33% of this tense · 67th percentile among 15 sector filers · read for itself

From the record

Park Ha Biological Technology Co., Ltd.'s filings since 2023 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

5.1/10

What has it actually done, year after year?

+9.6% a year over 4 filed years; profitable in 3 of 4.

weight 45% of this tense · 51st percentile among 15 sector filers · read for its customers

From the record

Park Ha Biological Technology Co., Ltd.'s 4 filed years say what it did: revenue went from $2 million in fiscal 2022 to $3 million in fiscal 2025, up 9.6% a year; it rose in 2 of 3 years; the deepest fall was 3% from fiscal 2023 to fiscal 2024; net income was positive in 3 of 4 of those years (its annual reports).

What it rests on

revenue growth over the filed span9.6%top 23% of its family
the share of years revenue rosebottom 47% of its family
the share of filed years with a profitbottom 17% of its family
the deepest fall from a revenue peak3.1%top 37% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

as filed

0.9/10

How has it treated the people who own it?

Share count grew 5.6% a year. 0% of cash flow returned. Insiders: 0 sales, 0 purchases.

weight 22% of this tense · 9th percentile among 13 sector filers · read for its shareholders

From the record

Over the 3 fiscal years to 2025-10-31, Park Ha Biological Technology Co., Ltd.'s diluted share count grew about 5.6% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

What it rests on

the share count over the yearsbottom 11% of its family
cash returned against operating cash flowbottom 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

4.3/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

4.7/10

Is it financially healthy right now?

ROE -610%: lost 610¢ per shareholder dollar. Leverage 33%: owes 33¢ per asset dollar.

weight 45% of this tense · 47th percentile among 15 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-10-31, Park Ha Biological Technology Co., Ltd. lost about 610 cents for every dollar of shareholders' money, and gross profitability: its products earned about 40 cents per dollar of everything the company owns. Leverage: it owed about 33 cents per dollar of assets, and net share issuance: its share count grew 17.8% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 17% of its family
return on equitybottom 3% of its family
gross profit against assetstop 10% of its family
the share count against the year beforebottom 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.2/10

How strong is its position in its industry?

bottom 32% of 15 in its family; net margin -965%.

weight 33% of this tense · 32nd percentile among 15 sector filers · read for its customers

From the record

Park Ha Biological Technology Co., Ltd.'s standing among 15 graded names in its industry family: revenue of $3 million in fiscal 2025 ranks in the bottom 4% by size; a net margin of -965% ranks in the bottom 10%; revenue growth of 9.6% a year over the last 3 filed years ranks in the top 17% (its annual reports).

What it rests on

revenue against the family$2.5Mbottom 4% of its family
net margin-965.0%bottom 10% of its family
three-year revenue growth9.6%top 17% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

4.9/10

What are the people in charge doing?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 12 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-04-07 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 12 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-04-07 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 12 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Park Ha Biological Technology Co., Ltd.'s leadership is put at 4.9 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-04-07 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 12 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.3/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

7.3/10

How much room does it have to grow?

top 27% of 15 in its family for room to expand.

weight 45% of this tense · 73rd percentile among 15 sector filers · read for itself

From the record

Park Ha Biological Technology Co., Ltd.'s room to grow, from the newest filed statements (fiscal 2025): cash of $4 million against no long-term debt tagged leaves 63.6% of its assets as net cash, top 3% of its family; cash from operations less capital spending is -0.1% of revenue (bottom 10%); a gross margin of 94.4% (top 3%); research spending of 9.4% of revenue (top 12%) (its annual report).

What it rests on

cash less debt against assets63.6%top 3% of its family
cash from operations less capital spending against revenue-0.1%bottom 10% of its family
gross margin94.4%top 3% of its family
research spending against revenue9.4%top 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

8.6/10

What could actually drive growth from here?

top 14% of 15 in its family for growth drivers.

weight 33% of this tense · 86th percentile among 15 sector filers · read for its customers

From the record

Park Ha Biological Technology Co., Ltd.'s growth drivers, from the filed years to fiscal 2025: revenue grew 9.6% a year over the last three filed years against 9.6% over all 4, speeding up (top 13% of its family); the newest year grew 6% (top 37%); research spending grew 57.7% a year (top 4%); capital spending grew 95.5% a year (top 3%) (its annual reports). Park Ha Biological Technology Co., Ltd. reported 3 product lines in fiscal 2025: Franchise Fees at $2 million (60%), Products Sales Nonfranchisees at $536 thousand (21%), Product Sales Franchisees at $478 thousand (19%); 2 of 3 grew against the year before (its annual report).

What it rests on

three-year growth against the whole span+0.0 points a yeartop 13% of its family
the newest year's revenue growth6.0%top 37% of its family
three-year growth of research spending57.7%top 4% of its family
three-year growth of capital spending95.5%top 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

1.1/10

Did its newest year beat what its own record pointed to?

bottom 11% of 14 in its family for expectations against reality.

weight 22% of this tense · 11th percentile among 14 sector filers · read for its shareholders

From the record

Park Ha Biological Technology Co., Ltd.'s newest year against its own record: revenue of $3 million in fiscal 2025 came in 4.8% below the $3 million its prior three years' pace pointed to (bottom 18% of its family); net income of $24 million against a prior three-year average of $507 thousand (bottom 4%); a net margin of a loss larger than its revenue against 21.6% before (bottom 11%) (its annual reports).

What it rests on

revenue against the prior three years' pace-4.8%bottom 18% of its family
net income against the prior three years' averagefive times below its prior average or morebottom 4% of its family
net margin against its prior averagedown more than 100 pointsbottom 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton BYAH · research, not advice